We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

4 hedge funds and large institutions have $4.15M invested in Intra-Cellular Therapies Inc. in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 389 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 395 → 4 (-391)

100% less capital invested

Capital invested by funds: $13.6B → $4.15M (-$13.6B)

100% less funds holding in top 10

Funds holding in top 10: 52 → 0 (-52)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 389

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
-391
Holders Change %
-98.99%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
-52
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
389
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$1.26B
2
BlackRock
BlackRock
New York
-$1.15B
3
PCM
Pentwater Capital Management
Florida
-$685M
4
HI
HBK Investments
Texas
-$578M
5
Norges Bank
Norges Bank
Norway
-$472M
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
301
Parallel Advisors
California
– -$261K -1,982 Closed
ARC
302
Advisor Resource Council
Texas
– -$221K -1,953 Closed
FT
303
Fiduciary Trust
Massachusetts
– -$256K -1,939 Closed
PCM
304
PenderFund Capital Management
British Columbia, Canada
– -$20.3K -1,900 Closed
SWM
305
SeaCrest Wealth Management
New York
– -$251K -1,900 Closed
CF
306
Corebridge Financial
Texas
– -$241K -1,827 Closed
SWA
307
SFMG Wealth Advisors
Texas
– -$231K -1,748 Closed
PCM
308
Polymer Capital Management
New York
– -$229K -1,737 Closed
CI Investments Inc
309
CI Investments Inc
Ontario, Canada
– -$227K -1,722 Closed
Raymond James Financial
310
Raymond James Financial
Florida
– -$227K -1,721 Closed
CPA
311
Capital Performance Advisors
California
– -$220K -1,664 Closed
CGH
312
Crossmark Global Holdings
Texas
– -$211K -1,603 Closed
CCM
313
Coldstream Capital Management
Washington
– -$211K -1,601 Closed
VA
314
Vident Advisory
Georgia
– -$209K -1,586 Closed
TRCT
315
Tower Research Capital (TRC)
New York
– -$207K -1,569 Closed
WMA
316
West Michigan Advisors
Michigan
– -$205K -1,552 Closed
CSP
317
Cary Street Partners
Virginia
– -$198K -1,500 Closed
BCM
318
Blume Capital Management
California
– -$165K -1,250 Closed
C
319
Covestor
United Kingdom
– -$163K -1,233 Closed
GWSG
320
GPS Wealth Strategies Group
Colorado
– -$132K -1,000 Closed
FFA
321
Farther Finance Advisors
California
– -$117K -884 Closed
S
322
SignatureFD
Georgia
– -$107K -813 Closed
GI
323
GAMMA Investing
California
– -$98.9K -750 Closed
GWM
324
Geneos Wealth Management
Colorado
– -$84.7K -642 Closed
LIM
325
Longfellow Investment Management
Massachusetts
– -$75.7K -574 Closed
11 12
13
14 15

ITCI Hedge Fund Activity: Q2 2025 in Review

4 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2025, worth a combined $4.15M — down 100% from $13.6B a quarter earlier.

Sellers outnumbered buyers: 389 funds closed out of ITCI and 0 opened new positions — a net loss of 389 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $1.26B sold.

  • 4 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2025, down from 395 in Q1 2025.
  • Funds reported $4.15M of Intra-Cellular Therapies Inc. stock for Q2 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2025 and 389 closed out, a net change of -389 holders.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2025 was Vanguard Group, an estimated $1.26B sold.

Based on aggregated 13F filings for Q2 2025.